Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Important paper from Japan published in Blood.
The authors have developed FVIII variants with increased specific activity, which can potentially be used for gene therapy in hemophilia A.
These would be the equivalent of the Padua variant for FIX and can be used at much lower doses.
Even when used at 1/30th of the dose of Roctavian in macaques, supraphysiological FVIII levels were achieved.
No human studies yet.”
Read the full article here.
Article: Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Authors: Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J. S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 19, 2026, 20:21Jonathan Penm: Julianne Chong Featured in Australian Pharmacist on Anticoagulation Stewardship
-
Jun 19, 2026, 20:18Yaariv Khaykin: Can Some Patients Safely Stop Blood Thinners After AF Ablation?
-
Jun 19, 2026, 20:18Ahmed Mohsen: How Should D-Dimer Be Interpreted in Pregnancy?
-
Jun 19, 2026, 20:17Konrad Zuzda: A Challenging Case of Heparin-Free VV-ECMO for High-Risk Airway Management
-
Jun 19, 2026, 19:52Andre W. Bourgoyne: Could Your Diet Help Prepare You for Surgery?
-
Jun 19, 2026, 18:00George Harston: How AI Is Supporting the Next Generation of Acute Stroke Care in AHA 2026 Guidelines
-
Jun 19, 2026, 17:49Jennifer Beauchamp: Exploring the New Era of Stroke Care at the 16th Annual Yatsu Day Symposium
-
Jun 19, 2026, 17:44Brian A Beh: How A Lacunar Stroke Changed Me
-
Jun 19, 2026, 17:40Cameron Bryer: Returning to Work After a Young Stroke Is Challenging but Possible